4/A: Zenas BioPharma Director Xiao Ting Corrects Beneficial Ownership in Amended SEC Filing

Xiao Ting, a director at Zenas BioPharma, files an amended SEC Form 4/A to correct the number of shares beneficially owned following a recent transaction.

Summary

• Xiao Ting, a director of Zenas BioPharma, filed an amended Form 4/A with the SEC on April 28, 2025.
• This amendment corrects a previous filing from February 11, 2025, which incorrectly stated the number of securities beneficially owned after a transaction.
• The corrected filing shows that Xiao Ting beneficially owns 10,000 shares of common stock following a purchase on February 7, 2025.
• The shares were purchased at a weighted average price of $7.76, with individual transactions ranging from $7.64 to $7.78.
• The original filing incorrectly reported the amount of securities beneficially owned following reported transactions as 47,000 shares.

Sentiment

Score: 5

Explanation: The document is a correction of a previous error, which is neutral. It doesn't indicate positive or negative performance, but the initial error is a slight negative.

Negatives

• The initial Form 4 filing contained an error regarding the number of shares beneficially owned.

Industry Context

This filing is a routine disclosure required by the SEC for corporate insiders, ensuring transparency in stock ownership and trading activities.

Stakeholder Impact

• Shareholders benefit from accurate reporting of insider transactions.

Key Dates

Keywords

Zenas BioPharma, Xiao Ting, SEC Form 4/A, Beneficial Ownership, Amendment, Director, Shares, Transaction